ophthalmologytimes4d
1-year results from HELIOS trial show stability or improvement in treating NPDR
The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was ...
Renal & Urology News1mon
Empagliflozin Not Tied to Risk for New Nonproliferative Diabetic Retinopathy
The risk for nonproliferative diabetic retinopathy progression was similar for empagliflozin vs DPP4i therapy. (HealthDay News) — Empagliflozin initiation is not associated with incident ...
Ocular Therapeutix shares SOLR-R enrollment progress, next steps AXPAXLI
Ocular Therapeutix (OCUL) plans to advance AXPAXLI in non-proliferative diabetic retinopathy, NPDR, and the Company’s strategic outlook for ...
Medscape8d
Prevalence of Dry Eye Syndrome and Diabetic Retinopathy in Type 2 Diabetic Patients
Background: This study was performed to assess the prevalence of dry eye syndrome and diabetic retinopathy (DR ... with mild non proliferative DR (NPDR), 34 patients (17.1%) with moderate NPDR ...
Healio5d
20 years of DRCR trials offer ‘fundamental contributions to clinical care’
Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients ...
Hosted on MSN1mon
Empagliflozin Not Tied to Risk for New Nonproliferative Diabetic Retinopathy
TUESDAY, Dec. 17, 2024 (HealthDay News) -- Empagliflozin initiation is not associated with incident nonproliferative diabetic retinopathy (NPDR) compared with initiation of a dipeptidyl peptidase ...
Business Insider15d
Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR
outlined exceptional clinical progress across its registrational program for AXPAXLI™ in wet age-related macular degeneration (wet AMD), plans to advance AXPAXLI in non-proliferative diabetic ...